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MYCN repression of Lifeguard/FAIM2 enhances
neuroblastoma aggressiveness
L Planells-Ferrer1, J Urresti1, A Soriano2, S Reix1, DM Murphy3, JC Ferreres4, F Borràs4, S Gallego2,4, RL Stallings3, RS Moubarak1,
MF Segura*,2 and JX Comella*,1
Neuroblastoma (NBL) is the most common solid tumor in infants and accounts for 15% of all pediatric cancer deaths. Several risk
factors predict NBL outcome: age at the time of diagnosis, stage, chromosome alterations and MYCN (V-Myc Avian
Myelocytomatosis Viral Oncogene Neuroblastoma-Derived Homolog) amplification, which characterizes the subset of the most
aggressive NBLs with an overall survival below 30%. MYCN-amplified tumors develop exceptional chemoresistance and
metastatic capacity. These properties have been linked to defects in the apoptotic machinery, either by silencing components of
the extrinsic apoptotic pathway (e.g. caspase-8) or by overexpression of antiapoptotic regulators (e.g. Bcl-2, Mcl-1 or FLIP). Very
little is known on the implication of death receptors and their antagonists in NBL. In this work, the expression levels of several
death receptor antagonists were analyzed in multiple human NBL data sets. We report that Lifeguard (LFG/FAIM2 (Fas apoptosis
inhibitory molecule 2)/NMP35) is downregulated in the most aggressive and undifferentiated tumors. Intringuingly, although LFG
has been initially characterized as an antiapoptotic protein, we have found a new association with NBL differentiation. Moreover,
LFG repression resulted in reduced cell adhesion, increased sphere growth and enhanced migration, thus conferring a higher
metastatic capacity to NBL cells. Furthermore, LFG expression was found to be directly repressed by MYCN at the transcriptional
level. Our data, which support a new functional role for a hitherto undiscovered MYCN target, provide a new link between MYCN
overexpression and increased NBL metastatic properties.
Cell Death and Disease (2014) 5, 1401; doi:10.1038/cddis.2014.356; published online 4 September 2014
Neuroblastoma (NBL) is the most common solid tumor of
infancy, accounting for 15% of all pediatric cancer deaths.
These tumors are very heterogeneous, with a clinical course
ranging from spontaneous regression to aggressive behavior.
Several risk factors predict NBL outcome: INSS (International
Neuroblastoma Staging System) tumor stage, age at diag-
nosis, INPC (International Neuroblastoma Pathology Classi-
fication) classification, DNA ploidy and MYCN (V-Myc Avian
Myelocytomatosis Viral Oncogene Neuroblastoma-Derived
Homolog) oncogene amplification, which characterizes the
subset of most aggressive NBLs with overall survival below
30%.1–3 MYCN-amplified tumors are characterized by excep-
tional chemoresistance and metastatic capacity. These
properties have been linked to defects in the apoptotic
arsenal, either by overexpression of the antiapoptotic regulators
of the mitochondrial pathway (e.g. Bcl-2, Mcl-1)4,5 or by
alteration of components of the extrinsic apoptotic pathway
(e.g. caspase-8).6–8 In fact, there is evidence that the extrinsic
pathway may serve as a checkpoint to guard cells from
MYCN-initiated tumorigenesis as MYCN-elevated levels
sensitize NBL cells to death receptor (DR)-induced cell death,
either by TRAIL, TNFa or FasL stimuli.9 To date, the main
mechanism underlying the lack of DR-induced apoptosis in
MYCN-amplified tumors has been methylation of the
caspase-8 promoter, which blocks its expression and renders
cells resistant to DR-induced cell death.7,10 However, the
correlation between MYCN amplification and caspase-8
silencing in tumor samples remains controversial; other
authors showed the inactivation of caspase-8 to be indepen-
dent of MYCN amplification and NBL prognosis.6 As MYCN
amplification and caspase-8 silencing may not occur simulta-
neously, alternative resistance mechanisms must exist, which
either block DR-induced cell death or switch DR signaling to
alternative functions. DR activity can also be modulated by DR
antagonists, which have been poorly characterized in the
context of NBLs. The present work sought to analyze the role
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of DR antagonists in NBL and their contribution to the
oncogenic properties of NBL cells. Several DR antagonists
were found to be differentially expressed in the highest-risk
NBL tumors, namely stage 4 MYCN-amplified NBLs. Among
these, FAIM2 (Fas apoptosis inhibitory molecule 2), most
commonly referred to as Lifeguard (LFG), correlates best with
worse overall survival of NBL patients. Furthermore, we show
that MYCN is able to repress directly LFG expression, which
results in increased oncogenic properties such as augmented
sphere formation, decreased adhesion and enhanced migra-
tion. Collectively, our results demonstrate a previously
unappreciated role of LFG, and support a new target for
therapeutic intervention against high-risk NBL.
Results
The DR antagonist LFG is downregulated in high-risk
NBL. The mRNA expression levels of antiapoptotic genes
known to modulate the extrinsic pathway in the neural
lineage were analyzed in independent human expression
and prognostic NBL data sets. Few DR modulators were
consistently altered in different NBL data sets. Table 1 shows
the fold change variation between stage 4 MYCN-amplified
tumors versus the rest of stages present in the respective
study (i.e. stages 1, 3 and 4 without MYCN amplification).
PEA15, CFLAR/FLIP and LFG were downregulated in
advanced stages of the disease. In particular, the highest
differential expression was found in stage 4 MYCN-amplified
patients, the group of NBLs with the worst prognosis
(Figure 1a). Whether the differences in gene expression
could be associated with patient outcome was also analyzed.
Notably, only low expression levels of LFG were associated
with worse overall survival (Figure 1b and Table 1).
Moreover, the association between LFG levels and patient
survival was maintained in MYCN non-amplified tumor
subsets (Supplementary Figure 1). These differences in
LFG expression levels were then validated in an independent
cohort of 38 primary tumor samples obtained at the Vall
d’Hebron Hospital (Supplementary Table 1). Quantitative
real-time PCR (qPCR) expression analysis revealed a
significant reduction in LFG levels in stage 4 and MYCN-
amplified tumors (Figure 1c). Western blot analyses
confirmed that differences in mRNA expression were also
found at the protein level (Figure 1d). In summary, we
conclude that LFG is the DR antagonist with the highest
differential expression and association with patient outcome
in high-risk NBL.
LFG is associated with NBL differentiation. When LFG
levels were correlated with a number of clinicopathologic
variables (i.e. age at diagnosis, site of primary tumor, site of
metastasis and histology), LFG expression was found
to be closely associated with tumors presenting unfavorable
histology (P¼ 0.0041) and MYCN amplification (P¼ 0.0121),
which are often undifferentiated tumors11 (Figure 2a and
Supplementary Table 2). With a view to ascertain the
association between tumor differentiation and LFG expres-
sion, we sought to characterize LFG levels in the different
status of NBL cell differentiation. On the one hand, all-trans
retinoic acid (RA)-mediated differentiation of NBL cell lines
increased LFG at mRNA and protein levels (Figures 2b and c).
TRKB was used as a neuronal differentiation marker12 to
confirm the differentiation response of the NBL cell lines to
the RA treatment. On the other hand, LFG levels were
analyzed in cells cultured in neurosphere formation medium
(serum-free and supplemented with EGF/FGF2), which
mimics undifferentiated status of NBL cells.13,14 When NBL
cell lines were seeded in neurosphere medium, cells formed
non-adherent spheres. LFG was found to be downregulated
in sphere medium-cultured cells compared with cells cultured
in standard conditions (P¼ 0.0286 for SK-N-BE(2) and IMR-
5; P¼ 0.0294 for IMR-32) (Figure 2d). We conclude that
LFG expression associates with the differentiation status of
NBL cells.
Reduction of LFG levels modulates proliferation,
adhesion and migration of NBL cells. To assess the role
of LFG in NBL oncogenic properties, loss-of-function experi-
ments were performed using two different short hairpin
(sh)RNA targeting LFG (Figure 3a). Both shLFG constructs
Table 1 Death receptor antagonist expression and correlation with survival in neuroblastoma data sets









FAIM FAIM1 NA 1.00 (¼0.6430) Low (¼ 0.419) NA
FAIM2 Lifeguard 3.33 (o0.0001) 3.22 (¼ 0.0002) Low (¼ 0.019) Low (¼1.76e 9)
FAIM3 TOSO  1.69 (¼0.2831) 1.00 (¼0.8994) High (¼0.675) NA
CFLAR FLIP  1.56 (¼0.0154) 2.43 (¼ 0.0235) Low (¼ 0.106) Low (¼0.978)
XIAP IAP3, BIRC4 1.57 (¼ 0.3988) 1.20 (¼ 0.0638) Low (¼ 0.128) NA
BIRC3 IAP2 3.57 (o0.0001) 1.28 (¼ 0.2423) Low (¼ 0.514) Low (¼0.026)
BIRC2 IAP1  1.19 (¼0.0011) 1.49 (¼ 0.0954) Low (¼ 7.01e 9) Low (¼5.6e 4)
TNFAIP3 A20 2.27 (o0.0001) 1.05 (¼0.2570) Low (¼ 0.459) Low (0.141)
BFAR BAR, RNF47 NA 1.55 (¼0.2570) High (¼0.001) High (¼ 0.024)
PTPN13 FAP-1 1.36 (¼ 0.1322) 1.19 (¼ 0.7333) High (¼0.24e3) NA
PEA15 HMAT1  1.33 (¼0.0154) 1.36 (¼ 0.0247) Low (¼ 0.367) NA
SUMO1 UBL1, PIC1 1.25 (¼ 0.0044) 2.27 (¼ 0.3990) High (¼0.547) High (¼ 0.031)
BTK ATK, XLA NA 1.20 (¼ 0.9880) High (¼0.373) Low (¼0.398)
Abbreviations: FC, fold change; NA, not available
Statistically significant P-values are highlighted in gray
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notably knocked down LFG at the protein level and reduced
proliferation of SH-SY5Y (P¼ 0.022 for shLFG and
P¼ 0.0238 for shLFG2) and CHLA-90 cells (P¼ 0.0043 for
shLFG and P¼ 0.022 for shLFG2) (Figure 3b). The most
efficient downregulation was achieved by shLFG, which was
used for the following experiments. Cell adhesion assays
showed that shLFG-transduced cells exhibit around 50%
reduction in adhesion to adherent plates compared with
scrambled (Scr)-infected cells (P¼ 0.0286 for SH-SY5Y and
P¼ 0.0043 for CHLA-90 cells) (Figure 3c). Moreover, when
NBL cells were seeded at low density, loss of LFG increased
non-adherent growth compared with the Scr shRNA
(Figure 3d). More than 10% of shLFG cells were able to
form viable spheres when they were seeded at low density in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 15% fetal bovine serum (FBS), whereas o4% of control
cells did so (P¼ 0.0066). Furthermore, shLFG-infected
cells showed a fourfold increased migration through the
8mm-transwell polycarbonate inserts (P¼ 0.0191) (Figure 3e).
The impact of these properties was further evaluated in vivo.
SH-SY5Y cells (shLFG or shScr) were injected into the flank
of female NMRI-Foxn1nu/Foxn1nu mice. Tumors appeared
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Figure 1 LFG is downregulated in high-risk NBL. (a) mRNA expression of the DR antagonists FLIP (1868_g_at), PEA15 (32260_at) and LFG (33293_at) in different NBL
stages obtained from GSE3960 data set. Data were analyzed by one-way ANOVA; *Po0.05, **Po0.01 and ***Po0.001. MNA, MYCN amplified. (b) Kaplan–Meier overall
survival curve in 251 tumors based on high or low LFG expression (probe A_23_P139891). (c) Relative LFG expression measured by qPCR in an independent cohort of NBL
primary tumors collected at Vall d’Hebron Hospital. Data were analyzed by one-way ANOVA; *Po0.05. (d) Western blot showing LFG expression in MYCN non-amplified
versus four MYCN-amplified primary NBL tumors. Naphtol blue (NB) staining was used as a loading control
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earlier in the LFG knockdown group (Figure 4a). No
significant differences in tumor growth or tumor weight were
found (Figures 4b and c). The presence of spontaneous
metastasis was evaluated in the lungs by ex vivo bioluminis-
cence (BLI) detection. Mice inoculated with LFG knockdown
cells showed increased metastatic burden in the lungs and
higher number of metastatic lesions (Figures 4d and e).
Taken together, these results indicate that the reduction on
LFG levels may contribute to altered adhesion properties and
increased metastatic potential of NBL cells.
LFG knockdown alters cell adhesion programs. To
enlighten the mechanism by which LFG knockdown reduces
cell adhesion and enhances migration properties of NBL
cells, we proceeded to LFG knockdown and performed a
whole transcriptome analysis by Affymetrix expression
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Figure 2 LFG levels are associated with NBL differentiation. (a) Relative LFG expression in histologically favorable (n¼ 30) versus unfavorable (n¼ 8) primary tumors.
mRNA levels were measured by qPCR. **Po0.01, unpaired t-test. (b) All-trans RA (10mM) induced differentiation in NBL cell lines SK-N-BE(2) and SH-SY5Y. LFG and TRKB
expression were measured by qPCR at the indicated time points. Data are presented as mean±S.E.M. of three independent experiments. (c) Western blot of LFG expression.
a-Tubulin was used as a loading control. Bands were quantified using Image J software (National Institutes of Health, Bethesda, MD, USA) and normalized expression values are
indicated. (d) LFG expression detection by qPCR in the indicated NBL cell lines cultured with standard conditions (Adherent) or using neurosphere medium (Sphere). *Po0.05,
unpaired t-test; data are represented as mean±S.E.M., n¼ 4. Images (right) show IMR-5 adherent and sphere-forming cultures. Scale bar, 100mm
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Figure 3 LFG knockdown favors the metastatic potential of NBL cell lines. (a) Western blot showing LFG downregulation after infection with shScr or shLFG lentiviruses
using anti-FAIM2 (H-21) antibody (Santa Cruz Biotechnology Inc). Bands were quantified and normalized versus a-tubulin. (b) Cell proliferation assay in SH-SY5Y and CHLA-
90 cells after LFG downregulation with two shRNA sets (shScr/shLFG and shScr2/shLFG2). Cells were fixed with 4% paraformaldehyde at the indicated time points. Data are
presented as mean±S.E.M. of three independent experiments. *Po0.05 and **Po0.01, unpaired t-test; * shScr versus shLFG; #shScr2 versus shLFG2. (c) Cell adhesion
assay of SH-SY5Y and CHLA-90 transduced with either Scr or LFG shRNAs, measured at the indicated time points. *Po0.05 and **Po0.01, unpaired t-test; data are
represented as mean±S.E.M., n¼ 3. (d) Sphere formation assay of shScr and shLFG SH-SY5Y cells seeded at low density in DMEMþ 15% FBS and kept in standard
culture conditions for 4 weeks. Graph represents the percentage of sphere formation. **Po0.01, unpaired t-test; data are presented as mean±S.E.M., n¼ 9. Infection
efficiency was monitored by visualization of green fluorescent protein (GFP). Scale bar, 100mm. (e) Transwell migration assay of shScr and shLFG-transduced SH-SY5Y cells.
Cells that migrated were quantified by WST-1 assay. *Po0.05, unpaired t-test; graphs show mean±S.E.M., n¼ 3
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arrays. Principal component analysis segregated the infected
cells (Scr versus shLFG), indicating a consistent transcrip-
tional impact of LFG knockdown (Supplementary Figure 2).
The Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis15,16 of genes differentially expressed in
response to LFG knockdown revealed a reproducible
modulation of genes mainly involved in cancer pathways
and adhesion processes (Figure 5a). Functional annotation
analysis showed a remarkable modulation of genes impli-
cated in focal adhesion, cell adhesion and adherent junctions
(Figure 5b), which supported an active role of LFG in the
tumorigenic properties of NBL cells. Array data were
validated by qPCR for FGF14, STK36, BCL2, RAP1A,
TJP1, ITGA9 and LFG (Figure 5c).
LFG expression is directly modulated by MYCN. As LFG
levels were significantly lower in MYCN-amplified tumors, we
sought to determine whether MYCN participates in LFG
repression. Our first approach consisted in using the SHEP
MYCN-inducible Tet21N cell line, which constitutively over-
expresses MYCN under the control of a tetracycline-
responsive repressor element.17 Doxycycline treatment of
Tet21N resulted in a differentiated phenotype (Figure 6a) and
reduced MYCN expression with a concomitant time-depen-
dent upregulation of LFG, both at the mRNA and protein level
(Figure 6b). Furthermore, the same result was obtained
when MYCN was silenced using an inducible shRNA in an
independent MYCN-amplified cell line such as IMR-32
(Supplementary Figure 4).
Tumor growth


















































































































Figure 4 LFG knockdown increases the metastatic potential of SH-SY5Y cells. (a) Xenograft formation assay with shScr and shLFG SH-SY5Y cells injected into the flank
of NMRI nude mice. (b) Tumor volume measured at different days postinjection using a digital caliper. Data are presented as mean±S.E.M. (c) Tumor weight measured after
surgery. Data are presented as mean±S.E.M. (d) Total BLI flux (photons/s) of lung metastases from shScr and shLFG SH-SY5Y-injected mice. Images are representative of
ex vivo BLI lung images. Pictures were set at the same scale to compare BLI between shScr and shLFG conditions. (e) Scoring of lung metastases. Data are shown as
mean±S.E.M. Images are representative of ex vivo BLI showing distant metastases in lungs disected from shScr and shLFG-injected mice
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To address whether MYCN represses LFG directly, a
chromatin immunoprecipitation (ChIP) data set was examined
for MYCN binding in Tet21N cells with and without doxy-
cycline treatment.18 A high confidence MYCN-binding peak
was identified in the LFG proximal promoter that disappeared
when MYCN expression was repressed by doxycycline
treatment (Figure 6c).
MYCN-mediated transcription repression is now consid-
ered to be at least as important as transcription activation.19
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Figure 5 LFG knockdown alters the expression of cell adhesion molecules. (a) KEGG pathway enrichment analysis of differentially expressed genes between shScr and
shLFG-transduced SH-SY5Y cells. (b) Gene set enrichment analysis performed on genes differentially expressed between shScr and shLFG SH-SY5Y cells. Heatmap shows
selected differentially expressed genes grouped in categories of functionally relevant pathways. (c) Array validation. qPCR using primers for three upregulated genes (FGF14,
STK36 and BCL2) and three downregulated genes (RAP1A, TJP1 and ITGA9). LFG levels have been included as a control of the experiment. Values are represented as fold
change versus shScr and are the mean±S.E.M. of three independent experimets
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Figure 6 MYCN represses directly LFG transcription. (a) Representative images of MYCN-Tet-off-inducible Tet21N cells treated with or without doxycycline (100 ng/ml).
Scale bar, 100mm. (b) Tet21N cell line treated with doxycycline (100 ng/ml) for the indicated times. LFG and MYCN mRNA levels were detected by qPCR and normalized
versus L27 (upper panel) and also detected by western blot (lower panel). Data on the graph are presented as mean±S.E.M., n¼ 3. a-Tubulin was used as a loading control.
Bands were quantified and normalized versus a-tubulin. (c) Identification of MYCN binding site at the LFG promoter (gene ID: FAIM2) by ChIP in Tet21N cells. The scale on the
top of the panel indicates position on chromosome 12. Green bars represent fluorescent intensity of probes around the FAIM2 promoter, expressed as log 2 ratios. The red bar
represents a high confidence MYCN peak, identified by the NimbleScan peak finding algorithm. (d) LFG levels measured by qPCR in the indicated cell lines treated with 1mM
of the DNA methyltransferase inhibitor 5-aza-20-deoxycytidine or 1 mM of the HDAC inhibitor sodium butyrate or for the indicated times. Mean±S.E.M., n¼ 3
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been proposed that MYCN may interact with transcription
factors or transcriptional complexes, inducing DNA and
histone modifications. To further characterize how MYCN
represses LFG transcription, MYCN-amplified NBL cell lines
were treated with the the DNA methyltransferase inhibitor
5-aza-2’-deoxycytidine and the histone deacetylase (HDAC)
inhibitor sodium butyrate (Figure 6d). Both treatments
induced an increase in LFG mRNA levels in all cell lines
tested, thereby suggesting that MYCN represses LFG
expression by favoring histone deacetylation and LFG DNA
promoter methylation.
Discussion
Alterations of key elements of the apoptotic pathway have
been shown to be determinant in the outcome of NBLs.
While characterization of the mitochondrial or intrinsic
pathway elements has been extensive, limited attention to
the components of the extrinsic or DR pathway has been
paid. The most characterized element of the extrinsic
pathway is caspase-8, which is lost in B70% of NBLs.6,20
Loss of caspase-8 has been shown to prevent DR-
induced apoptosis21–23 and potentiate NBL metastasis.24,25
However, caspase-8 can also be prometastatic if other
components of the apoptotic machinery are compromised.26
Whether other modulators of the intrinsic pathway can
impact similarly to caspase-8 in NBL behavior remain
understudied.
Here, we have analyzed the expression of several DR
antagonists in multiple NBL data sets and found that LFG was
the most differentially expressed DR antagonist in MYCN-
amplified tumors. LFG low levels were also found to correlate
with worse overall survival. LFG was originally reported to be
expressed exclusively in the nervous system and upregulated
during the development of rat sciatic nerve.27 Primary
functional analyses revealed that LFG is able to antagonize
FasL but not TNFa-induced cell death in T cells.28 We and
others confirmed that LFG is essential to prevent Fas-induced
apoptosis in neuronal cells29 by clustering with Fas receptor
and blocking caspase-8 activation.30 Recently, an alternative
LFG function has been proposed. Merianda and co-workers31
have demonstrated that LFG localization in axons is sufficient
to support axonal growth in dorsal root ganglionar cells,
thereby indicating that LFG may have DR antagonist-
independent functions. Alternative functions for other DR
antagonists are rare but not unique. In fact, the antiapoptotic
protein PEA15 has also been linked to NBL prognosis. High
levels of this protein correlate with favorable clinical features.
PEA15 was shown to block NBL migration through the
inhibition of ERK/RSK2 signaling, suggesting a metastatic
limiting role in the progression of NBL.32 Similar to PEA15,
loss of LFG potentiates cell detachment, adherence-indepen-
dent growth, migration and metastasis. However, the
mechanism seems to be quite different. LFG knockdown
impacted indirectly the modulation of cell adhesion and some
epithelial-to-mesenchymal (EMT) genes (Supplementary
Figure 3). One example is ITGA9, which is found to be
downregulated in shLFG-infected cells. ITGA9 has been
shown to be essential for the adhesion of rhabdomyosarcoma
cells.33 Other prometastatic integrins were found to be
upregulated (e.g. ITGAV, ITGB1). For example, overexpres-
sion of ITGAV has been found to correlate with metastasis of
laryngeal,34 hypopharyngeal squamous cell carcinomas35
and colorectal cancer.36 Moreover, ITGAV knockdown
decreased proliferation and increased apoptosis in Hep-2
carcinoma cells.35 Several tight-junction (TJ) genes were also
downregulated (e.g. TJP1). Loss of cohesion of the TJ
structure can lead to invasion and ultimately to the metastasis
of cancer cells.37 Regarding the EMT-related genes, we have
found upregulation of TWIST1 upon LFG knockdown and also
an inverse correlation in human samples (Supplementary
Figures 3a and b). TWIST1 is an important EMT and
metastasis promoter gene,38 which has been recently found
to to be overexpressed in MYCN-amplified NBL.39 By
contrast, ERBB3 and KRT19 genes were found to be reduced
in NBL cells infected with shLFG and downregulated in NBL
human samples with low levels of LFG. ERBB3 belongs to the
epidermal growth factor receptor family and participates in the
activation of proliferation40 and differentiation pathways,41
whereas KRT19 is a member of the keratin family and
participates in the organization of the cytoskeleton.42 The
expression of KRT19 or ERBB3 was found to be low in
patients with poor prognosis.39
Other genes such as FGF14, STK36 or BCL2 may
contribute in a different manner to the metastatic process.
STK36 is a serine/threonine kinase that has an important
role in the activation of the sonic hedgehog pathway,
reported to be essential for NBL proliferation and tumor
growth.43 The upregulation of BCL2 may also contribute to
inhibit apoptosis when cells grow in anchorage-independent
conditions.
Furthermore, we provide evidence that low expression of
LFG is not a mere association with the differentiation status
of the cell, but it is actively repressed by the MYCN
oncogene. MYCN encodes a protein with a basic helix–
loop–helix domain known to be a transcriptional regulator of
genes controlling cell cycle and proliferation, cell invasion,
angiogenesis and cell survival and death pathways
(reviewed in Westermark et al.11). MYCN has been shown
to participate in NBL metastasis by direct or indirect
repression of integrin subunits altering cell–matrix or
cell–cell interactions44 or repressing Caveolin-1, whose
downregulation elicits anchorage-independent growth and
tumor formation.45 We show that repression of LFG impacts
on the expression of several molecules that participate in
cell adhesion processes, recapitulating some of the MYCN
reported effects.
In summary, our results provide a new link between
MYCN amplification and early steps of NBL metastasis,
and the participation of LFG in unprecedented functions
such as cell adhesion, anchorage-independent growth and
migration.
Materials and Methods
Reagents. Unless otherwise indicated, all reagents were purchased from
Sigma-Aldrich (Barcelona, Spain). 5-Aza-2’-deoxycytidine was purchased from
Calbiochem (San Diego, CA, USA).
Analysis of mRNA NBL data sets. Gene expression data of 101 and 51
primary NBL tumors (GSE3960;46 GSE1623747) were used to analyze the
expression of DR antagonists. The expression of each individual DR antagonist
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was analyzed comparing the stage 4 MYCN-amplified tumors versus the other
stages present in the study (i.e. stages 1, 3 and 4 without MYCN amplification).
Gene expression data of human samples (GSE1647648 and Oberthuer lab data
set from Oncogenomics database) were used to generate Kaplan–Meier survival
analysis.
Human samples. Primary tumor tissue samples from 38 NBL patients
enrolled at the Vall d’Hebron Hospital (Barcelona, Spain) were obtained
immediately after surgery and snap frozen in liquid nitrogen and stored at
 80 1C until processing. Tumors were examined by the pathologist to confirm
NBL diagnosis and the presence of at least 80% of tumor tissue sample and
histopathologic classification. All patients gave written informed consent.
Gene expression analysis by qPCR. Total RNA was extracted from
NBL cell lines and tumor samples using the RNeasy Mini Kit (Qiagen, Las Matas,
Spain). Between 0.5 and 1mg of total RNA was retrotranscribed using High
Capacity RNA-to-cDNA Kit (Applied Biosystems, Alcobendas, Spain). Gene
expression analyses were performed using the LFG, TRKB, FGF14, STK36,
BCL2, RAP1A, TJP1 and ITGA9 Taqman probes. Unless otherwise indicated, all
expression analysis were normalized versus 18S housekeeping gene. MYCN
expression was performed with SYBR green (Applied Biosystems) and normalized
against L27 using the following primers: MYCN – forward, 50-CCTGAGCGATTCAG
ATGATGA-30 and reverse, 50-GGTGAATGTGGTGACAGCCT-30; L27 – forward,
50-AGCTGTCATCGTGAAGAA-30 and reverse, 50-CTTGGCGATCTTCTTCTTGCC-30.
Analysis was performed using the 7900HT Sequence Detection Systems 2.3
Software (Applied Biosystems). The relative fold change in expression was
determined by the comparative 2(DDCT) method.49
Western blot. Cell homogenates were obtained in lysis buffer (50 mM Tris, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton) and tissue homogenates were
obtained in RIPA buffer (Pierce/ThermoFisher Scientific, Lafayette, CO, USA),
both supplemented with 1EDTA-free complete protease inhibitor cocktail
(Roche, Sant Cugat del Vallès, Spain). Protein concentration was quantified by a
modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA, USA). Proteins
(20–30mg) were resolved in Tris/glycine SDS/PAGE gels and transferred to PVDF
membranes (Millipore, Billerica, MA, USA). After blocking with Tris-buffered saline
with Tween-20 containing 5% nonfat dry milk for 1 h at room temperature,
membranes were probed with anti-LFG (AnaSpec, Seraing, Belgium) or anti-
FAIM2 (H-21) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) when indicated,
and anti-a-tubulin or anti-MYCN NCM-II-100 (Abcam, Cambridge, UK) primary
antibodies overnight at 4 1C. Membranes were developed with SuperSignal Dura
Detection Kit (Pierce/ThermoFisher Scientific) or EZ-ECL Chemiluminescence
Detection Kit (Biological Industries, Kibbutz Beit-Haemek, Israel).
Cell lines. SH-SY5Y, IMR-32 and IMR-5 were acquired from the American
Type Tissue Collection (ATCC, Barcelona, Spain). CHLA-90 cells were obtained
from Children’s Oncology Group Cell Line and Xenograft Repository (Lubbock,
TX, USA). SK-N-BE(2) and LAI-5S cells were purchased from Public Health
England Culture Collections (Salisbury, UK). Tet21N cells were a generous gift
from Manfred Schwab (DKFZ, Heidelberg, Germany). IMR-32 cells transduced
with the conditional MYCN shRNA were kindkly provided by Dr Frank
Westermann (DKFZ, Heidelberg, Germany). All cell lines obtained directly from
the tissue banks were amplified and stored in liquid nitrogen. Upon resuscitation,
cells were maintained in culture for no more than 2 months. SH-SY5Y, IMR-5,
IMR-32 and LAI-5S cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 15% heat-inactivated FBS, 20 U/ml penicillin and 20 mg/ml
streptomycin. SK-N-BE(2) and CHLA-90 were maintained in Iscove’s modified
Dulbecco’s medium, supplemented with 20% heat-inactivated FBS, 1% of
insulin-transferrin-selenium, 100 U/ml penicillin and 100 mg/ml streptomycin.
Tet21N cells were grown in RPMI (Roswell Park Memorial Institute) 1640
medium (Invitrogen, Barcelona, Spain) supplemented with 10% heat-inactivated
FBS, 25 mM HEPES (Invitrogen), 200 mg/ml geneticin (G418), 0.5 mg/ml
amphotericin B, 10 mg/ml hygromycin B, 100 U/ml penicillin and 100 mg/ml
streptomycin. All cultures were maintained at 37 1C in a saturated atmosphere of
95% air and 5% CO2.
RA differentiation. Induction of differentiation of NBL cell lines was
performed as described previously by Encinas et al.12 Briefly, 6 105 cells
were seeded in 100 mm culture dishes previously coated with 65 mg/ml type I
collagen (BD Biosciences, San Agustin de Guadalix, Spain). All-trans RA was
added the next day at a final concentration of 10 mM and maintained during 1, 3
and 5 days.
Sphere formation. SK-N-BE(2), IMR-5 and IMR-32 cells were grown for
sphere formation in serum-free neurobasal medium (Invitrogen), supplemented
with B27 (Invitrogen), 2 mM L-glutamine (Invitrogen), 20 ng/ml EGF (ProSpec-Tany
Technogene Ltd, Ness-Ziona, Israel), 20 ng/ml FGF2 (ProSpec-Tany Technogene
Ltd), 20 U/ml penicillin and 20mg/ml streptomycin.
LFG knockdown. For loss-of-function experiments, two sets of
shRNA lentiviral constructs were used: shScr and shLFG were previously
described in Fernandez et al.30 and shScr2 and shLFG2 were purchased from
ThermoFisher Scientific (RHS4531-EG23017). Lentiviruses were propagated
using standard procedures.50,51 NBL cells were seeded at 2 106 cells per
60 mm dish and infected with viral supernatant for 12 h. The transduction
efficiency was evaluated 3 days later by scoring green fluorescent
protein (GFP)-positive cells. LFG knockdown was assessed by qPCR and
western blot.
Cell proliferation and adhesion assays. Infected NBL cells were
seeded in 96-well plates (2 104 cells/well for proliferation assays and 2 105
cells/well for adhesion assays) and incubated at 37 1C for the indicated times.
Then, cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal
violet. Crystals were dissolved in 10% acetic acid and the absorbance was
measured at 590 nm.
Migration assays. A suspension of 2.5 105 SH-SY5Y NBL cells was
added in serum-free media to 8-mm-pore cell culture inserts (Falcon Discovery
Labware; BD Biosciences). Cells were incubated for 8 h under standard culture
conditions and complete media in the lower part of the chamber. Viable cells that
had migrated to the lower transwell chamber were quantified by WST-1 assay
(Roche).
Xenografts. A total of 5 106 SH-SY5Y-pFLuc cells infected with shScr
(n¼ 10) or shLFG (n¼ 10) were injected in the flank of female NMRI nude mice in
300ml of phosphate-buffered saline (PBS) and Matrigel (1 : 1). Tumor growth was
measured every 2–3 days using an electronic caliper. At the respective scheduled
surgery, 150 mg/kg D-Luciferin substrate (Promega Biotech Iberica, Madrid, Spain)
was injected intraperitoneally 5 min before animals were killed. The primary tumor
mass was excised and weighted. Lungs were removed to detect distant
metastases. Each organ was immersed in a 300mg/ml D-Luciferin solution in PBS
and maintained in cold conditions until ex vivo BLI was performed using the IVIS
Spectrum from the CIBER-BBN In Vivo Experimental Platform located at Vall
d’Hebron Research Institute (VHIR).
mRNA microarray analysis. Expression profiling of triplicate experimental
sample groups (shScr versus shLFG) was performed using Affymetrix microarray
platform and the GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa Clara,
CA, USA). Two hundred nanograms of total RNA was hybridized to the arrays with
the GeneChip WT Terminal Labeling and Hybridization Kit (Affymetrix). Chips were
processed on an Affymetrix GeneChip Fluidics Station 450 and Scanner 3000 and
normalization of the raw data (CEL files) was carried out with Robust Multichip
Average algorithm.52 To filter and perform differential expression analyses, a
moderated t-test (Po0.05 a-level) and fold-change thresholding (433%
reproducible change) were considered. The functional annotations of resulting
gene lists were performed using the Gene Ontology53 and the KEGG15,16
databases. To build the heatmaps, array expression values were normalized to the
median and log 2 transformed. Values were converted to color scale using the
MultipleExperimentViewer software (TM4 Software Suite, Boston, MA, USA54).
ChIP assays. Details of the MYCN chip experiments, along with validation
studies, have been previously published by Murphy et al.18 Sites of enrichment
were identified using the normalized log 2 ratios and the NimbleScan peak finding
function.
Statistical analysis. Statistical significance was determined by unpaired
t-test or one-way ANOVA when indicated using GraphPad (GraphPad Prism
Software, La Jolla, CA, USA). *Po0.05, **Po0.01 and ***Po0.001.
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